Immunologic effects of hydroxyurea in sickle cell anemia

Pediatrics

Volumn 134, Issue 4, 2014, Pages 686-695

  Lederman, Howard M ^a   Connolly, Margaret A ^b   Kalpatthi, Ram ^c   Ware, Russell E ^d   Wang, Winfred C ^e   Luchtman Jones, Lori ^f   Waclawiw, Myron ^g   Goldsmith, Jonathan C ^g   Swift, Andrea ^a   Casella, James F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Clinical Trials & Surveys Corp   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Hydroxyurea; Immunology; Sickle cell disease; Vaccines

Indexed keywords

HYDROXYUREA; MEASLES MUMPS RUBELLA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; ANTISICKLING AGENT;

ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; IMMUNITY; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; MEMORY T LYMPHOCYTE; MULTICENTER STUDY (TOPIC); MUMPS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RUBELLA; SICKLE CELL ANEMIA; T LYMPHOCYTE SUBPOPULATION; ANEMIA, SICKLE CELL; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; IMMUNOLOGY; MULTICENTER STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYUREA; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84925279511     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-0571     Document Type: Article

References (27)

1. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932-938
2. Wang WC, Ware RE, Miller ST, et al; BABY HUG Investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377(9778):1663-1672
3. Barrett-Connor E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore). 1971;50(2):97-112
4. Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr 2003;143(4):438-444
5. Davies EG, Riddington C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database Syst Rev. 2004; (1):CD003885
6. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008;121(3):562-569
7. Charache S, Barton FB, Moore RD, et al; The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. Medicine (Baltimore). 1996;75(6):300-326
8. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ; Multicenter Study of Hydroxyurea. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood. 1997;89(3):1078-1088
9. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88(6):1960-1964
10. Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr. 1996;129(4):559-565
11. Donehower RC. Hydroxyurea. In: Chabner, BA, Longo, DL, eds. Cancer Chemotherapy and Biotherapy. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996:253-260
12. van Tilburg CM, Sanders EAM, Rovers MM, Wolfs TFW, Bierings MB. Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review. Leukemia. 2006;20(10):1717-1722
13. Ek T, Josefson M, Abrahamsson J. Multivariate analysis of the relation between immune dysfunction and treatment intensity in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;56(7):1078-1087
14. McFarland E. Immunizations for the immunocompromised child. Pediatr Ann. 1999;28(8):487-496
15. Nilsson A, De Milito A, Engström P, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics. 2002;109(6). Available at: www.pediatrics.org/cgi/content/full/109/6/e91
16. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J. Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilus influenzae type b. J Pediatr Hematol Oncol. 2004;26(11):727-734
17. American Cancer Society Web Site. Available at: www.cancer.org/treatment/treat-mentsandsideeffects/guidetocancerdrugs/hydroxyurea
18. Koskela M. Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination. Pediatr Infect Dis J. 1987; 6(6):519-526
19. Quataert SA, Kirch CS, Wiedl LJ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol. 1995;2(5):590-597
20. Plikaytis BD, Carlone GM, Turner SH, Gheesling LL, Holder PF Program ELISA User's Manual. Atlanta, GA: Centers for Disease Control and Prevention; 1993
21. Shearer WT, Rosenblatt HM, Gelman RS, et al; Pediatric AIDS Clinical Trials Group. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003;112(5): 973-980
22. Wong WY, Powars DR, Operskalski EA, et al; The Transfusion Safety Study Group. Blood transfusions and immunophenotypic alterations of lymphocyte subsets in sickle cell anemia. Blood. 1995;85(8):2091-2097
23. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25(19):3816-3826
24. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;130(3 suppl):S1-S24
25. Johnson CE, Kumar ML, Whitwell JK, et al. Antibody persistence after primary measlesmumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J. 1996; 15(8):687-692
26. American Academy of Pediatrics. In: Pickering L, ed. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012:489-499
27. Thornburg CD, Files BA, Luo Z, et al; BABY HUG Investigators. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012;120(22):4304-4310